E
IOVA icon

Ergoteles’s Iovance Biotherapeutics IOVA Stock Holding History

Ergoteles’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-166,172
Closed -$1.02M – 1254
2023
Q1 		$1.02M Buy
166,172
+26,759
+19% +$185K 0.04% 496
2022
Q4 		$891K Buy
139,413
+94,276
+209% +$736K 0.03% 497
2022
Q3 		$432K Buy
+45,137
New +$521K 0.02% 813
2022
Q2 		– Sell
-125,229
Closed -$2.08M – 1813
2022
Q1 		$2.08M Buy
125,229
+10,695
+9% +$165K 0.08% 252
2021
Q4 		$2.19M Buy
114,534
+2,700
+2% +$59.4K 0.09% 240
2021
Q3 		$2.76M Buy
111,834
+65,966
+144% +$1.55M 0.1% 220
2021
Q2 		$1.19M Sell
45,868
-153,379
-77% -$3.99M 0.03% 458
2021
Q1 		$6.31M Buy
199,247
+95,578
+92% +$3.96M 0.2% 138
2020
Q4 		$4.81M Buy
103,669
+40,317
+64% +$1.6M 0.16% 144
2020
Q3 		$2.09M Buy
+63,352
New +$1.94M 0.28% 65

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Ergoteles's IOVA Position: Q2 2023 in Review

Ergoteles sold out of Iovance Biotherapeutics (IOVA) in Q2 2023, closing a stake of 166,172 shares — an estimated $1.02M sold.

Ergoteles first reported a position in IOVA in Q3 2020 and held it in 10 quarters. The position peaked at $6.31M in Q1 2021. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.

  • Ergoteles reported no remaining Iovance Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 166,172 Iovance Biotherapeutics shares in Q2 2023, an estimated $1.02M.
  • Ergoteles first reported a position in Iovance Biotherapeutics in Q3 2020 and held it in 10 quarters.
  • Ergoteles's Iovance Biotherapeutics position peaked at $6.31M in Q1 2021.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.